Evidence map›Paper›PMID 25769714›Full record

ReviewSurgical oncology clinics of North America2015

Regional therapies for in-transit disease.

Paul J Speicher, Claire H Meriwether, Douglas S Tyler

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Surgical oncology clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Paul J SpeicherDepartment of Surgery, Duke University Medical Center, 2301 Erwin Road, Durham, NC 27710, USA.
Claire H MeriwetherDepartment of Surgery, Duke University Medical Center, 2301 Erwin Road, Durham, NC 27710, USA.
Douglas S TylerDepartment of Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA. Electronic address: doug.tyler@duke.edu.

Funding

Translational Research in Surgical OncologyT32CA093245 · NCI · DUKE UNIVERSITY · PI ALLEN, PETER J, HARPOLE, DAVID H. · 2002 to 2020
$5.2M
NCI NIH HHS T32 CA093245
6 · The paper itself

Abstract

In-transit melanoma is an uncommon pattern of recurrence, but presents unique management challenges and opportunities for treatment. The clinical presentation usually involves from 1 to more than 100 small subcutaneous or cutaneous nodules, ranging from submillimeter to multiple centimeters in diameter. Regional chemotherapy techniques are a mainstay of treatment of patients without systemic disease spread. Future applications of regional therapy are likely to involve combination therapy with cytotoxic agents and novel immune modulators. Regional therapy provides distinct opportunities for the treatment of unresectable disease, and offers a unique platform for investigation of novel therapeutics in early-stage clinical trials.

Indexed as

Antineoplastic AgentsChemotherapy, Cancer, Regional PerfusionHumansMelanomaNeoplasm Recurrence, LocalSkin NeoplasmsAntineoplastic AgentsIn-transit melanomaIsolated limb infusionIsolated limb perfusionRegional therapy

Identifiers

PMID25769714
PMCPMC5161093

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.